Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3257524rdf:typepubmed:Citationlld:pubmed
pubmed-article:3257524lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0001506lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0014432lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0025646lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0025647lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0596040lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C1511539lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0456378lld:lifeskim
pubmed-article:3257524lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:3257524pubmed:issue2lld:pubmed
pubmed-article:3257524pubmed:dateCreated1988-3-16lld:pubmed
pubmed-article:3257524pubmed:abstractTextWith 2',3'-O-isopropylideneadenosine or its N6-benzoyl derivative as starting material, synthetic routes to two novel adducts of L-methionine and beta,gamma-imido-ATP have been devised. One adduct, 14 (2:3 mixture of 6' epimers), had a P alpha OCH(R1)CH2 system [R1 = CH2-L-SCH2CH2CH2CH(NH2)CO2H] in place of the P alpha OC(5')H2 system of ATP, while the other, 16 (2:3 mixture of 5' epimers), had a P alpha OCH2CH2CH(R2) system [R2 = L-SCH2CH2CH(NH2)CO2H]. The ribose-P alpha bridge in 14 and 16 contained one more methylene group than in two homologous methionine-ATP adducts studied previously. Adduct 14 was a potent inhibitor of the rat M-2 (normal tissue) and M-T (Novikoff ascitic hepatoma) variants of methionine adenosyltransferase and gave competitive kinetics vs MgATP (Ki = 0.39 and 0.63 microM, respectively) or vs L-methionine (Ki = 2.2 and 2.7 microM). Adduct 16 was likewise a potent inhibitor competitive vs MgATP (Ki = 0.44 and 0.81 microM, respectively) or L-methionine (Ki = 2.1 and 1.5 microM). The kinetic data indicate that 14 and 16 inhibit by binding simultaneously to the MgATP and L-methionine substrate sites and that the extra methylene group facilitates the interaction of their methionine residues with these methionine sites.lld:pubmed
pubmed-article:3257524pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:languageenglld:pubmed
pubmed-article:3257524pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:citationSubsetIMlld:pubmed
pubmed-article:3257524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3257524pubmed:statusMEDLINElld:pubmed
pubmed-article:3257524pubmed:monthFeblld:pubmed
pubmed-article:3257524pubmed:issn0022-2623lld:pubmed
pubmed-article:3257524pubmed:authorpubmed-author:HamptonAAlld:pubmed
pubmed-article:3257524pubmed:authorpubmed-author:KapplerFFlld:pubmed
pubmed-article:3257524pubmed:authorpubmed-author:VrudhulaV MVMlld:pubmed
pubmed-article:3257524pubmed:issnTypePrintlld:pubmed
pubmed-article:3257524pubmed:volume31lld:pubmed
pubmed-article:3257524pubmed:ownerNLMlld:pubmed
pubmed-article:3257524pubmed:authorsCompleteYlld:pubmed
pubmed-article:3257524pubmed:pagination384-9lld:pubmed
pubmed-article:3257524pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:meshHeadingpubmed-meshheading:3257524-...lld:pubmed
pubmed-article:3257524pubmed:year1988lld:pubmed
pubmed-article:3257524pubmed:articleTitleToward the synthesis of isozyme-specific enzyme inhibitors. Potent inhibitors of rat methionine adenosyltransferases. Effect of one-atom elongation of the ribose-P alpha bridge in two covalent adducts of L-methionine and beta,gamma-imido-ATP.lld:pubmed
pubmed-article:3257524pubmed:affiliationInstitute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.lld:pubmed
pubmed-article:3257524pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3257524pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3257524pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:3257524lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3257524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3257524lld:pubmed